Jean Sébastien Guillamo

Author

Also Known As

Edouard Marcel Gueye, F. Vandenbos-Burel, J Guillamo, J S Guillamo, J. S. Guillamo, J.-S. Guillamo, J.S. Guillamo, J.S.G. Guillamo, Jean Sebastien Guillamo, Jean Sébastien Guillamo

Publications

998

Citations

H-Index

Concepts

All Affiliations

Pitié-Salpêtrière Hospital Sorbonne Université Inserm Hôpital de la Timone Centre Hospitalier Universitaire de Caen Normandie

About

Jean Sébastien Guillamo is an author at Pitié-Salpêtrière Hospital specializing in medicine, glioma, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	215
2	Health Sciences	3	3	50
3	Pharmacology	3	3	140
4	Neurology	2	2	50
5	Pathology	1	1	37

Jean Sébastien Guillamo

Publications

772

Citations

H-Index

Page 1

	Year	Citations
Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): A retrospective study of 104 patients Jean Sébastien Guillamo, Alain Créange, C Kalifa, Brain	2002	283
Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas R L Costa de Oliveira, Christo Christov, Jean Sébastien Guillamo, BMC Cell Biology	2005	151
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF Bruno Chauffert, L. Feuvret, Franck Bonnetain, Annals of Oncology Temavir StudyNeuro-oncologyTemozolomide-based ChemoradiationOncologyRadiation Therapy	2014	94
Migration Pathways of Human Glioblastoma Cells Xenografted into the Immunosuppressed Rat Brain Jean Sébastien Guillamo, Fabrice Lisovoski, Christo Christov, Journal of Neuro-Oncology	2001	62
Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations Dominique Figarella‐Branger, Karima Mokhtari, Caroline Dehais, Neuro-Oncology	2014	61
Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study withSainte‐Anne malignancy grade, growth fractionand patient survival Pascale Varlet, Jean Sébastien Guillamo, F. Nataf, Neuropathology and Applied Neurobiology Tumoral PathologyAngiogenesisGliomaMib-1 Labelling IndexMedicine	2000	37
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors Karina Vera, L. Djafari, Sandrine Faivre, Annals of Oncology Neuro-oncologyDose-dense RegimenOncologyMedicineMetronomic Therapy	2003	34
Ongoing Clinical Trials Joanna Clarke, Marguerite Ennis, Kathleen R. Lamborn, Neuro-Oncology Clinical Trial ManagementClinical EndpointClinical TrialsRandomized Controlled TrialMedicine	2010	22
Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Anocef phase II trial. Germán Reyes-Botero, Jérôme Honnorat, Olivier Chinot, Journal of Clinical Oncology Elderly PatientsCancer ManagementPharmacotherapyHigh-grade GliomasPoor Performance Status	2013	16
Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group. Bruno Chauffert, L. Feuvret, Franck Bonnetain, Journal of Clinical Oncology ImmunotherapeuticsHigh-grade GliomasControl ArmGliomaRelapsed Gbm	2011	12

Page 1